No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years.

Abstract

The appropriate dose of progestogen during long-cycle hormone replacement is still under debate. We present preliminary two-year results from an open five-year clinical trial of 132 postmenopausal women. All subjects had long-cycle HRT consisting of 70 days 2 mg oestradiol valerate (E(2)V), followed by 14 days 2 mg E(2)V plus 20 mg medroxyprogesterone acetate, and a seven-day hormone-free period. No endometrial samples with hyperplasia or indicative of malignancy were found at 24 months.

• Authors: Risto Erkkola, Ulpu Kumento, Sirpa Lehmuskoski, Leena Mattila, Mika Mustonen
• Journal: The journal of the British Menopause Society (J Br Menopause Soc) Vol. 8 Issue 4 Pg. 155-6 (Dec 2002) ISSN: 1362-1807 [Print] England
• PMID: 12804325 (Publication Type: Journal Article)